Besides Life Biosciences, how many companies will reach a human partial-reprogramming trial by 30 Jun 2028?
Chance it happens
92%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together.
Outcomes
Resolution criteria
The number of companies with a dosed first patient in a registered partial-reprogramming trial as of 2028-06-30. Resolution horizon: 2028-06-30. Source: ClinicalTrials.gov.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a company press release stating that Life Biosciences has dosed the first patient in a Phase 1 trial of ER-100 for optic neuropathies. It directly bears on the forecasting question because the resolution hinges on companies achieving a first-patient-dosed human partial-reprogramming trial, though this page concerns Life Biosciences itself rather than additional companies.
This is a company press release stating that the FDA cleared Life Biosciences' IND for ER-100 and that its first-in-human Phase 1 study (NCT07290244) can begin. It directly bears on the forecast because it identifies a partial-reprogramming program reaching the human clinical-trial stage, while also clarifying that this company is the excluded reference case in the question.
This is a Fight Aging! news post reporting that the FDA cleared Life Biosciences' IND for ER-100 and that the company is preparing a first-in-human partial-reprogramming study. It is relevant because it supports the premise that Life Biosciences is likely to be the first company into a registered human partial-reprogramming trial, which informs forecasts about how many other companies may follow by 2028-06-30.
This is a news article reporting that the FDA cleared Life Biosciences to begin a human study using partial epigenetic reprogramming. It is relevant because it establishes that at least one company in this modality reached the threshold of an authorized human trial, which informs the field baseline for forecasting how many additional companies may do so by 2028-06-30.
This Facebook post summarizes a June 2026 announcement that Life Biosciences dosed the first patient in its Phase 1 ER-100 partial epigenetic reprogramming trial using OCT4, SOX2, and KLF4. It is relevant as background on the state of the field, though the prediction explicitly asks for companies besides Life Biosciences.
This appears to be a scientific review article hosted on PubMed Central about partial cellular reprogramming. It is relevant because it likely summarizes the state of the field, key companies, and translational progress, which informs prognosis for how many firms may reach a registered human partial-reprogramming trial by 2028.
This appears to be a JD Supra legal/news article about FDA approval of a Phase 1 clinical trial involving Life Biosciences, likely in partial reprogramming. It bears on the prognosis because it is direct evidence that at least one company in the space had advanced to human-trial stage, even though the forecast asks for companies besides Life Biosciences.